5 stories found
Senior executives and board members at several publicly traded companies, including Smucker, CrowdStrike, and Brinker International, have filed disclosures for substantial share sales. The transactions represent routine insider divestments rather than coordinated market activity.
An analysis questions if CAMP4 THERAPEUTICS (CAMP) stock is undervalued as the company approaches key clinical development milestones for its CMP-002 program.
Daniel Tardiff, the Chief Scientific Officer of Camp4 Therapeutics, has sold $8,272 worth of common stock.
Camp4 Therapeutics, Atossa Therapeutics, and Tvardi Therapeutics have reported their GAAP Earnings Per Share (EPS). Some of these companies' EPS figures missed analyst estimates.
Several companies, including Talon Metals Corp., Nu Holdings, NUGL, BranchOut Food, Atrium Therapeutics, Camp4 Therapeutics, Tenon Medical, ARS Pharmaceuticals, Eledon Pharmaceuticals, Techprecision, and 4D Molecular Therapeutics, have released their second-quarter earnings reports, with varying results in EPS and revenue.